Celcuity Inc. CELC 深 滬
交易中 12-12 11:02:31 美东时间
109.75
+8.980
+8.91%
華盛通- 最 高112.64
- 今 開102.895
- 成交量 41.89万股
- 最 低 102.38
- 昨 收 100.77
- 總市值 50.78亿
- 52周最高 112.64
- 市盈率 靜 --
- 換手率 0.91%
- 52周最低 7.575
- 委 比 34.75%
- 總股本 4627.13万
- 歷史最高 112.64
- 量 比 2.34
- 振 幅 10.18%
- 歷史最低 4.03
- 每 手 1
- 風險率 28.41%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Celcuity Announces Updated Results From Randomized, Phase 3 VIKTORIA-1 Trial For Gedatolisib, At 2025 SABCS
For patients whose time to progression on immediate prior therapy was >18 months, median progression-free survival ("PFS") was 12.4 months with gedatolisib + palbociclib + fulvestrant ("gedatolisib triplet") and 10.0
12-12 03:38
美股大行评级 | 最高500美元！MongoDB获18家大行紧急上调目标价；巴克莱下调理想汽车目标价至18美元
今日重点评级关注：B. Riley证券：维持Seabridge Gold"买入"评级，目标价从50美元升至65美元；HC Wainwright & Co.：维持TRX Gold"买入"评级，目标价从1.2美元升至1.4美元
12-03 09:58
Jefferies Maintains Buy on Celcuity, Raises Price Target to $134
Jefferies analyst Maury Raycroft maintains Celcuity (NASDAQ:CELC) with a Buy and raises the price target from $108 to $134.
12-02 19:42
Celcuity To Present at Upcoming 8th Annual Evercore Healthcare Conference
<p>MINNEAPOLIS, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the 8th Annual Evercore Healthcare Conference to be held in Miami, Florida on December 2-4, 2025.</p> <p>Brian Sullivan, Chief Executive Officer and Co-founder of Celcuity, is scheduled for a fireside chat at 7:30 a.m. ET on Wednesday, D...
11-26 12:05
美股大行评级 | Stifel上调英伟达目标价升至250美元；大摩上调哔哩哔哩目标价升至27美元；NICE遭多家机构下调目标价
今日重点评级关注：Oppenheimer：维持Olema Pharmaceuticals"跑赢大市"评级，目标价从22美元升至45美元；Bernstein：维持Atlassian"跑赢大市"评级，目标价从290美元升至304美元
11-19 11:01
美股大行评级 | Stifel上调特斯拉目标价升至508美元；多家大行上调Vita Coco目标价最高至58美元
今日重点评级关注：HC Wainwright & Co.：维持Oncolytics Biotech"买入"评级，目标价从5美元升至10美元；HC Wainwright & Co.：维持Barinthus Biotherapeutics"买入"评级，目标价从3美元升至4美元
11-18 15:28
Celcuity Submits NDA for Gedatolisib to FDA
An update from Celcuity ( ($CELC) ) is now available. On November 17, 2025, Cel...
11-18 05:57
Celcuity Analyst No Longer Bullish Despite Breast Cancer Therapy Application
FDA accepts NDA for Celcuity's advanced breast cancer therapy. Analyst downgrades stock due to high valuation. Next catalyst is topline data.
11-17 23:13
华尔街顶级分析师最新评级：戴尔遭下调评级
华尔街最受关注、且能影响市场走势的研究评级报告现已汇总如下。以下是由 The Fly 整理的今日投资者需重点关注的分析师评级变动信息。 五大评级上调案例：...
11-17 22:51
美股大行评级 | 思科、On Holding、派拓网络等获多家机构上调目标价；Circle 遭富国、德银等多家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持PDS Biotechnology"买入"评级，目标价从13美元升至15美元；HC Wainwright & Co.：维持PepGen Inc."买入"评级，目标价从18美元升至20美元
11-14 10:43
